Ex	O
Vivo	O
Oncolytic	B:C1563738
Virotherapy	I:C1563738
with	O
Myxoma	O
Virus	I:C0027150
Arms	O
Multiple	O
Allogeneic	O
Bone	I:C0398533
Marrow	I:C0398533
Transplant	I:C0398533
Leukocytes	O
to	O
Enhance	O
Graft	O
versus	I:C0600555
Tumor	I:C0600555
.	O

Ex	O
Vivo	O
Oncolytic	O
Virotherapy	I:C1563738
with	O
Myxoma	B:C0027150
Virus	I:C0027150
Arms	O
Multiple	O
Allogeneic	O
Bone	I:C0398533
Marrow	I:C0398533
Transplant	I:C0398533
Leukocytes	O
to	O
Enhance	O
Graft	O
versus	I:C0600555
Tumor	I:C0600555
.	O

Ex	O
Vivo	O
Oncolytic	O
Virotherapy	I:C1563738
with	O
Myxoma	O
Virus	I:C0027150
Arms	O
Multiple	O
Allogeneic	B:C0398533
Bone	I:C0398533
Marrow	I:C0398533
Transplant	I:C0398533
Leukocytes	O
to	O
Enhance	O
Graft	O
versus	I:C0600555
Tumor	I:C0600555
.	O

Ex	O
Vivo	O
Oncolytic	O
Virotherapy	I:C1563738
with	O
Myxoma	O
Virus	I:C0027150
Arms	O
Multiple	O
Allogeneic	O
Bone	I:C0398533
Marrow	I:C0398533
Transplant	I:C0398533
Leukocytes	B:C0023516
to	O
Enhance	O
Graft	O
versus	I:C0600555
Tumor	I:C0600555
.	O

Ex	O
Vivo	O
Oncolytic	O
Virotherapy	I:C1563738
with	O
Myxoma	O
Virus	I:C0027150
Arms	O
Multiple	O
Allogeneic	O
Bone	I:C0398533
Marrow	I:C0398533
Transplant	I:C0398533
Leukocytes	O
to	O
Enhance	O
Graft	B:C0600555
versus	I:C0600555
Tumor	I:C0600555
.	O

Allogeneic	B:C4255274
stem	I:C4255274
cell	I:C4255274
transplant	I:C4255274
-	O
derived	O
T	O
cells	I:C0039194
have	O
the	O
potential	O
to	O
seek	O
and	O
eliminate	O
sites	O
of	O
residual	O
cancer	I:C0242594
that	O
escaped	O
primary	O
therapy	I:C1708063
.	O

Allogeneic	O
stem	I:C4255274
cell	I:C4255274
transplant	I:C4255274
-	O
derived	O
T	B:C0039194
cells	I:C0039194
have	O
the	O
potential	O
to	O
seek	O
and	O
eliminate	O
sites	O
of	O
residual	O
cancer	I:C0242594
that	O
escaped	O
primary	O
therapy	I:C1708063
.	O

Allogeneic	O
stem	I:C4255274
cell	I:C4255274
transplant	I:C4255274
-	O
derived	O
T	O
cells	I:C0039194
have	O
the	O
potential	O
to	O
seek	O
and	O
eliminate	O
sites	O
of	O
residual	B:C0242594
cancer	I:C0242594
that	O
escaped	O
primary	O
therapy	I:C1708063
.	O

Allogeneic	O
stem	I:C4255274
cell	I:C4255274
transplant	I:C4255274
-	O
derived	O
T	O
cells	I:C0039194
have	O
the	O
potential	O
to	O
seek	O
and	O
eliminate	O
sites	O
of	O
residual	O
cancer	I:C0242594
that	O
escaped	O
primary	B:C1708063
therapy	I:C1708063
.	O

Oncolytic	O
myxoma	B:C0027150
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	B:C0027150
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	B:C0003392
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	B:C1707887
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	B:C0086418
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	B:C0027651
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	B:C0026764
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	B:C0026764
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	B:C0040732
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	B:C0039194
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	B:C0027651
killers	O
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Oncolytic	O
myxoma	O
virus	I:C0027150
(	O
myxoma	O
virus	I:C0027150
)	O
exhibits	O
potent	O
anti-cancer	O
efficacy	O
against	O
human	O
cancers	O
like	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
and	O
can	O
arm	O
transplant	O
-	O
derived	O
T	O
cells	I:C0039194
to	O
become	O
more	O
effective	O
cancer	O
killers	B:C1752435
in	O
vitro	O
and	O
in	O
an	O
immunodeficient	O
xenotransplant	O
murine	O
model	O
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	B:C0027150
virus	I:C0027150
virotherapy	O
against	O
residual	O
murine	O
multiple	O
myeloma	I:C0026764
in	O
immunocompetent	O
mice	O
using	O
an	O
allogeneic	O
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
virotherapy	B:C1563738
against	O
residual	O
murine	O
multiple	O
myeloma	I:C0026764
in	O
immunocompetent	O
mice	O
using	O
an	O
allogeneic	O
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
virotherapy	O
against	O
residual	O
murine	B:C0025929
multiple	O
myeloma	I:C0026764
in	O
immunocompetent	O
mice	O
using	O
an	O
allogeneic	O
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
virotherapy	O
against	O
residual	O
murine	O
multiple	B:C0026764
myeloma	I:C0026764
in	O
immunocompetent	O
mice	O
using	O
an	O
allogeneic	O
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
virotherapy	O
against	O
residual	O
murine	O
multiple	O
myeloma	I:C0026764
in	O
immunocompetent	B:C1512656
mice	O
using	O
an	O
allogeneic	O
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
virotherapy	O
against	O
residual	O
murine	O
multiple	O
myeloma	I:C0026764
in	O
immunocompetent	O
mice	B:C0025929
using	O
an	O
allogeneic	O
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

Here	O
,	O
we	O
tested	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
virotherapy	O
against	O
residual	O
murine	O
multiple	O
myeloma	I:C0026764
in	O
immunocompetent	O
mice	O
using	O
an	O
allogeneic	B:C2986594
mouse	I:C2986594
-	I:C2986594
mouse	I:C2986594
model	I:C2986594
.	O

In	O
contrast	O
to	O
all	O
human	B:C0682523
MM	I:C0682523
cell	I:C0682523
lines	I:C0682523
previously	O
tested	O
,	O
the	O
murine	O
MM	I:C1513528
cell	I:C1513528
line	I:C1513528
tested	O
here	O
was	O
highly	O
resistant	O
to	O
direct	O
myxoma	O
virus	I:C0027150
infection	O
and	O
oncolysis	O
in	O
vitro	O
.	O

In	O
contrast	O
to	O
all	O
human	O
MM	I:C0682523
cell	I:C0682523
lines	I:C0682523
previously	O
tested	O
,	O
the	O
murine	B:C1513528
MM	I:C1513528
cell	I:C1513528
line	I:C1513528
tested	O
here	O
was	O
highly	O
resistant	O
to	O
direct	O
myxoma	O
virus	I:C0027150
infection	O
and	O
oncolysis	O
in	O
vitro	O
.	O

In	O
contrast	O
to	O
all	O
human	O
MM	I:C0682523
cell	I:C0682523
lines	I:C0682523
previously	O
tested	O
,	O
the	O
murine	O
MM	I:C1513528
cell	I:C1513528
line	I:C1513528
tested	O
here	O
was	O
highly	O
resistant	O
to	O
direct	O
myxoma	B:C0027150
virus	I:C0027150
infection	O
and	O
oncolysis	O
in	O
vitro	O
.	O

In	O
contrast	O
to	O
all	O
human	O
MM	I:C0682523
cell	I:C0682523
lines	I:C0682523
previously	O
tested	O
,	O
the	O
murine	O
MM	I:C1513528
cell	I:C1513528
line	I:C1513528
tested	O
here	O
was	O
highly	O
resistant	O
to	O
direct	O
myxoma	O
virus	I:C0027150
infection	B:C3714514
and	O
oncolysis	O
in	O
vitro	O
.	O

In	O
contrast	O
to	O
all	O
human	O
MM	I:C0682523
cell	I:C0682523
lines	I:C0682523
previously	O
tested	O
,	O
the	O
murine	O
MM	I:C1513528
cell	I:C1513528
line	I:C1513528
tested	O
here	O
was	O
highly	O
resistant	O
to	O
direct	O
myxoma	O
virus	I:C0027150
infection	O
and	O
oncolysis	B:C0333516
in	O
vitro	O
.	O

Despite	O
this	O
in	O
vitro	O
resistance	O
,	O
we	O
found	O
that	O
ex	O
vivo	O
myxoma	B:C0027150
virus	I:C0027150
-	O
armed	O
allogeneic	O
bone	I:C0149615
marrow	I:C0149615
(	I:C0149615
BM	I:C0149615
)	I:C0149615
transplantation	I:C0149615
dramatically	O
ablated	O
pre-seeded	O
residual	O
multiple	O
myeloma	I:C0026764
in	O
vivo	I:C1515655
.	O

Despite	O
this	O
in	O
vitro	O
resistance	O
,	O
we	O
found	O
that	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
-	O
armed	O
allogeneic	B:C0149615
bone	I:C0149615
marrow	I:C0149615
(	I:C0149615
BM	I:C0149615
)	I:C0149615
transplantation	I:C0149615
dramatically	O
ablated	O
pre-seeded	O
residual	O
multiple	O
myeloma	I:C0026764
in	O
vivo	I:C1515655
.	O

Despite	O
this	O
in	O
vitro	O
resistance	O
,	O
we	O
found	O
that	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
-	O
armed	O
allogeneic	O
bone	I:C0149615
marrow	I:C0149615
(	I:C0149615
BM	I:C0149615
)	I:C0149615
transplantation	I:C0149615
dramatically	O
ablated	O
pre-seeded	O
residual	O
multiple	B:C0026764
myeloma	I:C0026764
in	O
vivo	I:C1515655
.	O

Despite	O
this	O
in	O
vitro	O
resistance	O
,	O
we	O
found	O
that	O
ex	O
vivo	O
myxoma	O
virus	I:C0027150
-	O
armed	O
allogeneic	O
bone	I:C0149615
marrow	I:C0149615
(	I:C0149615
BM	I:C0149615
)	I:C0149615
transplantation	I:C0149615
dramatically	O
ablated	O
pre-seeded	O
residual	O
multiple	O
myeloma	I:C0026764
in	B:C1515655
vivo	I:C1515655
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	B:C0027950
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	O
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	B:C0039194
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	O
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	B:C0007613
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	O
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	B:C0007634
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	O
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	B:C0027150
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	O
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	B:C0007634
enhanced	O
multiple	O
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	B:C0026764
myeloma	I:C0026764
killing	O
.	O

Unexpectedly	O
,	O
we	O
show	O
that	O
both	O
neutrophils	O
and	O
activated	O
T	O
cells	I:C0039194
from	O
the	O
donor	O
function	I:C0007613
as	O
virus	O
-	I:C0007634
armed	I:C0007634
carrier	I:C0007634
cells	I:C0007634
,	O
and	O
myxoma	O
virus	I:C0027150
-	O
preloaded	O
cells	O
enhanced	O
multiple	O
myeloma	I:C0026764
killing	B:C1752435
.	O

Our	O
results	O
demonstrate	O
a	O
novel	O
therapeutic	O
paradigm	O
for	O
residual	B:C0242594
cancer	I:C0242594
,	O
in	O
which	O
multiple	O
classes	O
of	O
allotransplant	O
leukocytes	O
can	O
be	O
armed	O
by	O
myxoma	O
virus	I:C0027150
ex	O
vivo	O
to	O
enhance	O
the	O
graft	O
-	I:C0600555
versus	I:C0600555
-	I:C0600555
tumor	I:C0600555
effects	I:C0600555
.	O

Our	O
results	O
demonstrate	O
a	O
novel	O
therapeutic	O
paradigm	O
for	O
residual	O
cancer	I:C0242594
,	O
in	O
which	O
multiple	O
classes	O
of	O
allotransplant	B:C0040739
leukocytes	O
can	O
be	O
armed	O
by	O
myxoma	O
virus	I:C0027150
ex	O
vivo	O
to	O
enhance	O
the	O
graft	O
-	I:C0600555
versus	I:C0600555
-	I:C0600555
tumor	I:C0600555
effects	I:C0600555
.	O

Our	O
results	O
demonstrate	O
a	O
novel	O
therapeutic	O
paradigm	O
for	O
residual	O
cancer	I:C0242594
,	O
in	O
which	O
multiple	O
classes	O
of	O
allotransplant	O
leukocytes	B:C0023516
can	O
be	O
armed	O
by	O
myxoma	O
virus	I:C0027150
ex	O
vivo	O
to	O
enhance	O
the	O
graft	O
-	I:C0600555
versus	I:C0600555
-	I:C0600555
tumor	I:C0600555
effects	I:C0600555
.	O

Our	O
results	O
demonstrate	O
a	O
novel	O
therapeutic	O
paradigm	O
for	O
residual	O
cancer	I:C0242594
,	O
in	O
which	O
multiple	O
classes	O
of	O
allotransplant	O
leukocytes	O
can	O
be	O
armed	O
by	O
myxoma	B:C0027150
virus	I:C0027150
ex	O
vivo	O
to	O
enhance	O
the	O
graft	O
-	I:C0600555
versus	I:C0600555
-	I:C0600555
tumor	I:C0600555
effects	I:C0600555
.	O

Our	O
results	O
demonstrate	O
a	O
novel	O
therapeutic	O
paradigm	O
for	O
residual	O
cancer	I:C0242594
,	O
in	O
which	O
multiple	O
classes	O
of	O
allotransplant	O
leukocytes	O
can	O
be	O
armed	O
by	O
myxoma	O
virus	I:C0027150
ex	O
vivo	O
to	O
enhance	O
the	O
graft	B:C0600555
-	I:C0600555
versus	I:C0600555
-	I:C0600555
tumor	I:C0600555
effects	I:C0600555
.	O

